Research Use Only: This product is supplied for laboratory research and in-vitro studies. Not for human or veterinary administration.
Hover to zoom
Identity Verified: LC-MS
(0 Reviews)
Tesamorelin (2mg)
- Synthetic GHRH Analog: 44-amino acid polypeptide with N-terminal trans-3-hexenoic acid modification, enhanced DPP-IV resistance, 26-38 min half-life vs. minutes for native GHRH, 150+ publications
- Physiological GH Axis Modulation: Selective GHRH-R agonist preserving pulsatile GH secretion patterns, 15.2% VAT reduction at 26 weeks, IGF-1 feedback regulation intact, no continuous GH elevation
- Clinical Status: FDA-approved Egrifta (2010) for HIV-associated lipodystrophy, Egrifta WR (F8 formulation, March 2025) weekly reconstitution, ongoing research in neurocognitive function/hepatic fat
- Mechanistic pathway studies
- In vitro receptor profiling
- HPLC verified identity and purity
$19.00In Stock
Ships same-day if ordered before 2PM EST
1
Encrypted Checkout
Global Express
Research Overview
Tesamorelin (2mg) - Modified GHRH Analog Research Peptide Molecular Profile: Tesamorelin is a 44-amino acid synthetic GHRH analog comprising the complete native GHRH(1-44) sequence with critical N-terminal trans-3-hexenoic acid modification. Molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S, molecular weight ~5,135.9 Da, CAS 218949-48-5. The hexenoyl modification confers DPP-IV resistance, extending half-life from minutes (native GHRH) to 26-38 minutes, with Tmax ~8-10 minutes post-administration. Mechanism of Action: Tesamorelin selectively activates GHRH receptors on pituitary somatotrophs, triggering the Gs-cAMP-PKA cascade. Gs protein activation stimulates adenylyl cyclase, elevating cAMP, which activates PKA. PKA phosphorylates CREB transcription factors, increasing GH gene transcription and synthesis. Calcium-dependent exocytosis releases GH granules. Preserves pulsatile GH secretion with IGF-1 feedback regulation. FDA-approved (Egrifta) for HIV lipodystrophy. Research Applications: This 2mg format is designed for initial receptor binding studies, DPP-IV resistance research, and comparative GHRH analog analysis. Product Specifications: - Purity: ≥98% (HPLC verified) - Form: Lyophilized powder - Content: 2 mg net peptide per vial - Storage: -20°C, protected from light and moisture - Certificate of Analysis provided Laboratory Use Only: This product is intended strictly for in-vitro research applications. NOT FOR HUMAN CONSUMPTION. FDA-approved drug substance (Egrifta). Intended for qualified researchers only.
This product is intended exclusively for in vitro laboratory research by qualified professionals. Not for human consumption. Not approved by the FDA.
Published Research Briefs
Our research team has published evidence-checked briefs covering the science behind this compound. Each brief reviews primary sources and grades claims independently.